EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma

Parvin Pourmasoumi iD, Farshid Zamani, Mohammad Bayat, Abdollah Amini

International Journal of Nanomedicine · 2026

DOI: 10.2147/ijn.s643605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Parvin Pourmasoumi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Temozolomide, Chitosan, Bevacizumab, Glioma. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Glioblastoma (GBM) has a poor prognosis, and temozolomide (TMZ) therapy is limited by a short half-life and insufficient intratumoral availability. We developed a bevacizumab (BVZ)-functionalized, exosome-associated chitosan nanocomposite loaded with TMZ (BVZ-Exo@CS-TMZ) as a multifunctional biohybrid platform for experimental glioma therapy.

Methods

CS-TMZ nanoparticles were prepared by ionotropic gelation, non-covalently associated with adipose-derived stromal cell exosomes (Exo), and functionalized with BVZ via EDC/NHS conjugation to accessible surface carboxyl groups. The Exo preparation was characterized by Western blotting, while the final formulation was characterized by FTIR, XRD, FESEM, TEM, DLS, zeta potential, and VEGF-binding ELISA. Apparent TMZ retention, loading, and release were quantified by UV-visible spectrophotometry. Biological activity was evaluated in C6 glioma cells and in a proof-of-concept intracerebral C6 glioma-bearing rat model.

Results

BVZ-Exo@CS-TMZ showed quasi-spherical morphology, a hydrodynamic diameter of 195.6 ± 6.7 nm, a PDI of 0.21 ± 0.03, and a zeta potential of -50.12 mV. Western blotting detected the EV-associated markers CD9, CD63, and CD81 in the Exo preparation, whereas calnexin was not detected. ELISA showed 74.9 ± 2.9% retained VEGF-binding activity after conjugation and washing. Apparent TMZ entrapment efficiency was 68.50 ± 2.15%, with a final trehalose-free loading of 15.96 ± 0.18 wt%. Apparent release over 96 h was acid-accelerated (Korsmeyer-Peppas n = 0.448-0.497). In C6 cells, the formulation reduced metabolic viability to 37.9% and lowered the TMZ-equivalent apparent IC5 0 from 99.4 to 55.6 µM. In vivo, it produced the smallest tumour area and fewest H&E-defined vascular-like regions, with increased Tp53, Bax, and Casp3 transcripts and reduced pri-/pre-miR-21 precursor RNA.

Conclusion

These findings support BVZ-Exo@CS-TMZ as a proof-of-concept EV-associated chitosan nanomedicine strategy for experimental glioma. Further pharmacokinetic, biodistribution, safety, and mechanistic validation in more clinically relevant glioblastoma models is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideChitosanBevacizumabGliomaNanocompositesExosomesBrain NeoplasmsAnimalsRatsCell Line, TumorApoptosisMaleDacarbazineAntineoplastic Agents, Alkylating

Stichwörter der Autor:innen

bevacizumabchitosanexosomesglioblastomananomedicinetemozolomide

Substanzen

TemozolomideChitosanBevacizumabDacarbazineAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Biomedical Engineering, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
  • Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Parvin Pourmasoumi

Zitieren

APA

Pourmasoumi, P., Zamani, F., Bayat, M., & Amini, A. (2026). Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s643605

Vancouver

Pourmasoumi P, Zamani F, Bayat M, Amini A. Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s643605

BibTeX
@article{Pourmasoumi2026,
  author = {Pourmasoumi, Parvin and Zamani, Farshid and Bayat, Mohammad and Amini, Abdollah},
  title = {Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  doi = {10.2147/ijn.s643605}
}
Kostenlos starten →